Tuberc Respir Dis.  2002 Apr;52(4):309-316.

Clinical Efficacy of Combination Chemotherapy with Ifosfamide Cisplatin, and Etoposide(ICE) in Advanced Non-Small Cell Lung Cancer

• Lee G
• Kim BD
• Kang HJ
• Lee SW
• Oh HA
• Bae SH
• Lee JL
• Lee KH
• Hyun MS
• Shin KC
• Jung JH
• Lee KH
• Ryu HM

Abstract

BACKGROUND: To evaluate the efficacy and toxicity of combination chemotherapy using ifosfamide, cisplatin, and etoposide in patients with advanced non-small cell lung cancer(NSCLC). MATERIALS AND METHODS: Thirty-three patients with inoperable NSCLC(stage III b+IV) who had measurable diseases, and had not been treated with chemotherapeutic drugs, were enrolled in this study(from March 1995 to December 1996). The patients received ifosfamide(1500mg/m2/day, a full drop with Mesna on days 1-5), Cisplatin (80mg/m2/day infusion with a hydration on day 2), and Etoposide (100mg/m2/day infusion for 2 hours on days 1-3). The treatment was repeated every 4 weeks.
RESULTS
Ten patients showed a partial responses (30.3%). The overall survival time of the responders was longer than that of the non-responders (median 55 vs 22 weeks, p=0.01). The toxicities of this treatment were tolerable. Grade 3 or 4 leukopenia was observed in 21%. There was 1 death related to febrile neutropenia. The non-hematologic toxicity was mild. The relative dose intensity given to the patients was 0.86 ifosfamide, 0.87 cisplatin, and 0.89 etoposide, showing an average dose intensity of 0.87.
CONCLUSIONS
A combination regimen of ifosfamide, cisplatin, and etoposide is effective and tolerable for treating advanced non-small cell lung cancer.

Keyword

Ifosfamide; Cisplatin; Etoposide; g Non-small-cell lung cancer; Chemotherapy

MeSH Terms

Carcinoma, Non-Small-Cell Lung*
Cisplatin*
Drug Therapy
Drug Therapy, Combination*
Etoposide
Febrile Neutropenia
Humans
Ifosfamide*
Leukopenia
Lung
Mesna
Cisplatin
Etoposide
Ifosfamide
Mesna